On March 19, 2020, Mr. Katkin, the Principal Executive Officer of the Urovant Sciences Ltd. and a member of Board, delivered a notice to the Company of his resignation as the Principal Executive Officer of the Company and as a member of the company's Board, effective as of March 23, 2020. On March 23, 2020, following the resignation of Mr. Katkin as the Principal Executive Officer, the Board appointed Mr. Robinson, age 50, to serve as the company's Principal Executive Officer. Mr. Robinson has served as a member of the company's Board since March 2019.

There are no arrangements or understandings between Mr. Robinson and any other persons pursuant to which he was selected as an officer, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Most recently, from April 2019 to March 2020, Mr. Robinson served as President and Chief Operating Officer at Paragon Biosciences, where he oversaw Paragon's operations and also served as the Chief Executive Officer of Qlarity Imaging, a Paragon portfolio company. Previously, from March 2018 to April 2019, Mr. Robinson served as the President and Chief Operating Officer of Alkermes Inc. where he was responsible for global commercial, new product planning, corporate planning, manufacturing, quality, human resource and business development functions. Prior to Alkermes, Mr. Robinson spent over twelve years at Astellas U.S. – most recently as President, Americas Operations, from April 2016 through February 2018, where his responsibilities included all aspects of operations for North and South America.